OBJECTIVES: To evaluate retrospectively the diagnostic yield, safety, and risk factors for diagnostic failure of computed tomography (CT) fluoroscopy-guided renal tumour biopsy. METHODS: Biopsies were performed for 208 tumours (mean diameter 2.3 cm; median diameter 2.1 cm; range 0.9-8.5 cm) in 199 patients. One hundred and ninety-nine tumours were ≤4 cm. All 208 initial procedures were divided into diagnostic success and failure groups. Multiple variables related to the patients, lesions, and procedures were assessed to determine the risk factors for diagnostic failure. RESULTS: After performing 208 initial and nine repeat biopsies, 180 malignancies and 15 benign tumours were pathologically diagnosed, whereas 13 were not diagnosed. In 117 procedures, 118 Grade I and one Grade IIIa adverse events (AEs) occurred. Neither Grade ≥IIIb AEs nor tumour seeding were observed within a median follow-up period of 13.7 months. Logistic regression analysis revealed only small tumour size (≤1.5 cm; odds ratio 3.750; 95% confidence interval 1.362-10.326; P = 0.011) to be a significant risk factor for diagnostic failure. CONCLUSION: CT fluoroscopy-guided renal tumour biopsy is a safe procedure with a high diagnostic yield. A small tumour size (≤1.5 cm) is a significant risk factor for diagnostic failure. KEY POINTS: • CT fluoroscopy-guided renal tumour biopsy has a high diagnostic yield. • CT fluoroscopy-guided renal tumour biopsy is safe. • Small tumour size (≤1.5 cm) is a risk factor for diagnostic failure.
OBJECTIVES: To evaluate retrospectively the diagnostic yield, safety, and risk factors for diagnostic failure of computed tomography (CT) fluoroscopy-guided renal tumour biopsy. METHODS: Biopsies were performed for 208 tumours (mean diameter 2.3 cm; median diameter 2.1 cm; range 0.9-8.5 cm) in 199 patients. One hundred and ninety-nine tumours were ≤4 cm. All 208 initial procedures were divided into diagnostic success and failure groups. Multiple variables related to the patients, lesions, and procedures were assessed to determine the risk factors for diagnostic failure. RESULTS: After performing 208 initial and nine repeat biopsies, 180 malignancies and 15 benign tumours were pathologically diagnosed, whereas 13 were not diagnosed. In 117 procedures, 118 Grade I and one Grade IIIa adverse events (AEs) occurred. Neither Grade ≥IIIb AEs nor tumour seeding were observed within a median follow-up period of 13.7 months. Logistic regression analysis revealed only small tumour size (≤1.5 cm; odds ratio 3.750; 95% confidence interval 1.362-10.326; P = 0.011) to be a significant risk factor for diagnostic failure. CONCLUSION: CT fluoroscopy-guided renal tumour biopsy is a safe procedure with a high diagnostic yield. A small tumour size (≤1.5 cm) is a significant risk factor for diagnostic failure. KEY POINTS: • CT fluoroscopy-guided renal tumour biopsy has a high diagnostic yield. • CT fluoroscopy-guided renal tumour biopsy is safe. • Small tumour size (≤1.5 cm) is a risk factor for diagnostic failure.
Authors: Michael J Leveridge; Antonio Finelli; John R Kachura; Andrew Evans; Hannah Chung; Daniel A Shiff; Kimberly Fernandes; Michael A S Jewett Journal: Eur Urol Date: 2011-06-24 Impact factor: 20.096
Authors: Alessandro Volpe; Antonio Finelli; Inderbir S Gill; Michael A S Jewett; Guido Martignoni; Thomas J Polascik; Mesut Remzi; Robert G Uzzo Journal: Eur Urol Date: 2012-05-12 Impact factor: 20.096
Authors: Alberto Breda; Eric G Treat; Leah Haft-Candell; John T Leppert; Jonathan D Harper; Jonathan Said; Steven Raman; Robert B Smith; Arie S Belldegrun; Peter G Schulam Journal: BJU Int Date: 2009-11-02 Impact factor: 5.588
Authors: Alessandro Volpe; Kamal Mattar; Antonio Finelli; John R Kachura; Andrew J Evans; William R Geddie; Michael A S Jewett Journal: J Urol Date: 2008-10-18 Impact factor: 7.450
Authors: Matvey Tsivian; Edward N Rampersaud; Maria del Pilar Laguna Pes; Steven Joniau; Raymond J Leveillee; William B Shingleton; Monish Aron; Charles Y Kim; Angelo M DeMarzo; Mihir M Desai; James D Meler; James F Donovan; Hans Christoph Klingler; David R Sopko; John F Madden; Michael Marberger; Michael N Ferrandino; Thomas J Polascik Journal: BJU Int Date: 2014-01-17 Impact factor: 5.588